Eli Lilly 2012 Annual Report Download - page 163

Download and view the complete annual report

Please find page 163 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

We will make a signicant contribution to humanity by
meaningful benets for the people who depend on us.
erating the ow of innovative medicines that provide
Alzheimer’s disease—a disease that has so far deed the
best eorts of medical science. While most of the public
advance a multifaceted eort. (Please see pages 6–9.)
markets, we met our nancial performance goals, and
reects our resolute commitment to innovation, and
exemplies the work of Lilly scientists in neuroscience,
to do. But our scientic achievements and operating
performance in 2012 strengthen our condence that new
continue to ow from our laboratories.
© 2013 Eli Lilly and Company YEAR2012AR
For more than 136 years, Lilly has demonstrated its
commitment to be a responsible global citizen. Today,
our understanding of corporate responsibility is evolv-
ing beyond philanthropy and reaching into the core of
our business operations.
Increasingly, we’re bringing to the table our business
assets and expertise, along with our nancial resourc-
es, to address global health challenges. And we’re cre-
ating shared value—for society and for Lilly—through
efforts that include partnering with leading global
health organizations to nd new solutions to the rising
burden of non-communicable diseases (NCDs).
All told, our corporate responsibility efforts can be
summed up in two goals: Advancing health. Improving life.
Advancing health. Our vision as a company is to make a
signicant contribution to humanity by improving global
health in the 21st century. We do this, rst and fore-
most, by creating innovative medicines that help people
live longer, healthier, more active lives.
We’re also spearheading broad, strategic partnerships
to improve access to health care and reduce hunger.
For example:
• The Lilly NCD Partnership, launched in 2011, will
provide $30 million over ve years to ght NCDs in
developing nations, with an emphasis on diabetes.
• The Lilly MDR-TB Partnership, launched in 2003,
works to build health care provider capacity and
access to needed drugs in order to improve care for
ADVANCING HEALTH. IMPROVING LIFE.
For more information on Lilly’s commitment to corporate responsibility
www.lilly.com/responsibility
For more information on Lilly’s commitment to transparency and links to
• Lilly Clinical Trial Registry
• Lilly Grant Registry
• Lilly Physician Payment Registry
• Lilly Political Contributions
www.lilly.com/about/business-practices/Pages/transparency.aspx
For more information on Lilly and pharmaceutical industry patient-assistance programs
Lilly TruAssist:
www.lillytruassist.com
or call toll-free 1.855.LLY.TRUE (1.855.559.8783)
Partnership for Prescription Assistance (program sponsored by America’s pharmaceutical research companies):
www.pparx.org
For perspectives on health care innovation
LillyPAD, an ofcial blog of Eli Lilly and Company:
lillypad.lilly.com
people suffering from deadly multidrug-resistant
tuberculosis.
• In 2011, we announced Lilly TruAssist, an easy-to-
use, one-stop resource for the U.S.-based patient-
assistance programs that we have long offered to
help people obtain the Lilly medications they need.
• Through a partnership with Heifer International®,
our Elanco animal health business aims to bring
100,000 families worldwide out of hunger.
Improving life. We’re committed to maintaining a sup-
portive working environment, serving our local commu-
nities, and reducing our environmental footprint.
We put special emphasis on exibility in the workplace,
and we were honored to have been named as Diversity-
Inc’s Top Company for Working Families in 2012. We also
provide opportunities for our employees to share their
expertise with communities around the world through
Connecting Hearts Abroad, a program that sends 200
Lilly ambassadors each year on two-week community
development assignments in Asia, Africa, and Central
and South America.
Our commitment to corporate responsibility is reected
in our ongoing support for the United Nations Global
Compact’s 10 principles related to human rights, labor,
the environment, and anticorruption.
You can review our performance across all areas of our
business in our 2011/2012 Lilly Corporate Responsibility
Update at www.lilly.com/responsibility/our-approach.